One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. (Q48358526)

10 February 2018

title

One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. (English)

1 reference

10 February 2018

Weijun Zhu

3

0 references

author name string

Wenbo Yu

1

1 reference

10 February 2018

Qing Fang

2

1 reference

10 February 2018

Haibo Wang

4

1 reference

10 February 2018

Po Tien

5

1 reference

10 February 2018

Linqi Zhang

6

1 reference

10 February 2018

Zhiwei Chen

7

1 reference

10 February 2018

language of work or name

English

0 references

publication date

30 December 2009

1 reference

10 February 2018

published in

Vaccine

1 reference

10 February 2018

volume

28

1 reference

10 February 2018

issue

9

1 reference

10 February 2018

page(s)

2088-2096

1 reference

10 February 2018

Smallpox vaccination: a review, part II. Adverse events

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The threat of smallpox and bioterrorism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Smallpox and Bioterrorism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Smallpox vaccination and ischemic coronary events in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Frequency of adverse events after vaccination with different vaccinia strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Anticipating smallpox and monkeypox outbreaks: complications of the smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Risks of smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The vaccinia virus A14.5L gene encodes a hydrophobic 53-amino-acid virion membrane protein that enhances virulence in mice and is conserved among vertebrate poxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Vaccinia virus expression vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Smallpox vaccine. A tame virus runs amok

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Vaccinia virus host range genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Vaccinia virus-encoded elF-2α homolog abrogates the antiviral effect of interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Antibody responses to vaccinia membrane proteins after smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

Molecular attenuation of vaccinia virus: mutant generation and animal characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

Mapping of a vaccinia host range sequence by insertion into the viral thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.038

7 January 2021

Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene

1 reference

12 December 2020

Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase

1 reference

12 December 2020

The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes.

1 reference

12 December 2020

Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection

1 reference

12 December 2020

10.1016/J.VACCINE.2009.12.038

Identifiers

DOI

1 reference

10 February 2018

0 references

1 reference

10 February 2018